Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 3
2001 5
2002 7
2003 9
2004 15
2005 11
2006 5
2007 7
2008 7
2009 6
2010 5
2011 6
2012 3
2013 4
2014 1
2015 4
2017 1
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Metreleptin treatment of non-HIV lipodystrophy syndromes.
Chevalier B, Lemaitre M, Leguier L, Mapihan KL, Douillard C, Jannin A, Espiard S, Vantyghem MC. Chevalier B, et al. Presse Med. 2021 Nov;50(3):104070. doi: 10.1016/j.lpm.2021.104070. Epub 2021 Sep 24. Presse Med. 2021. PMID: 34571177 Review.
HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS. Wierzbicki AS, et al. Curr Med Res Opin. 2008 Mar;24(3):609-24. doi: 10.1185/030079908X272742. Curr Med Res Opin. 2008. PMID: 18208641 Review.
SCOPE: This article provides an overview of the HIV-associated lipodystrophy, its pathogenesis and its clinical consequences (based on a search strategy in PubMed including literature published to November 2007). ...Robust diagnostic criteria are required for lipodystrophy …
SCOPE: This article provides an overview of the HIV-associated lipodystrophy, its pathogenesis and its clinical consequences (based o …
Thiazolidinediones in the treatment of type 2 diabetes.
Pittas AG, Greenberg AS. Pittas AG, et al. Expert Opin Pharmacother. 2002 May;3(5):529-40. doi: 10.1517/14656566.3.5.529. Expert Opin Pharmacother. 2002. PMID: 11996632 Review.
TZDs act by activating peroxisome proliferator-activated receptor (PPAR) phi a nuclear receptor implicated not only in lipid and glucose metabolism but other physiological functions as well. TZDs may have wide clinical applications beyond DM-2, as they can potentially be u …
TZDs act by activating peroxisome proliferator-activated receptor (PPAR) phi a nuclear receptor implicated not only in lipid and glucose met …
Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'.
Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall HJ. Balasubramanyam A, et al. Curr Opin Lipidol. 2004 Feb;15(1):59-67. doi: 10.1097/00041433-200402000-00011. Curr Opin Lipidol. 2004. PMID: 15166810 Review.
Identification of rationally based therapies requires an understanding of the mechanistic basis of HADL. RECENT FINDINGS: A case definition for HIV lipodystrophy, based on age, gender, duration of HIV disease, serum HDL cholesterol and anthropometry, provides high d …
Identification of rationally based therapies requires an understanding of the mechanistic basis of HADL. RECENT FINDINGS: A case definition …
Complications of HIV: lipodystrophy, anemia, renal, cardiovascular, and bone diseases.
Balt CA, Nixon H. Balt CA, et al. Nurse Pract Forum. 2001 Dec;12(4):199-213. Nurse Pract Forum. 2001. PMID: 11889688 Review.
A detailed explanation of the lipodystrophy syndrome and its common metabolic manifestations will be presented, including current research. In addition, the etiology, clinical findings, diagnosis, and treatment of the most common comorbid diseases associated with anemia an …
A detailed explanation of the lipodystrophy syndrome and its common metabolic manifestations will be presented, including current research. …
Plastic surgical options for HIV-associated lipodystrophy.
Nelson L, Stewart KJ. Nelson L, et al. J Plast Reconstr Aesthet Surg. 2008;61(4):359-65. doi: 10.1016/j.bjps.2007.11.014. Epub 2007 Dec 21. J Plast Reconstr Aesthet Surg. 2008. PMID: 18155655 Review.
Based on a literature search conducted using OVID Medline, this review shall describe the various treatment options employed by plastic surgeons to deal with the problems of fat distribution in patients suffering from HIV-lipodystrophy, and examine the evidence for …
Based on a literature search conducted using OVID Medline, this review shall describe the various treatment options employed by plastic surg …
Pharmacologic therapy for HIV-associated lipodystrophy.
Benavides S, Nahata MC. Benavides S, et al. Ann Pharmacother. 2004 Mar;38(3):448-57. doi: 10.1345/aph.1D081. Epub 2004 Jan 30. Ann Pharmacother. 2004. PMID: 14755064 Review.
DATA SYNTHESIS: Lipodystrophy has become more prevalent in patients with HIV. Lipodystrophy consists of adipose redistribution and metabolic abnormalities including dyslipidemia and insulin resistance. ...
DATA SYNTHESIS: Lipodystrophy has become more prevalent in patients with HIV. Lipodystrophy consists of adipose redistribution …
Therapy for HIV: past, present, and future.
Peters BS, Conway K. Peters BS, et al. Adv Dent Res. 2011 Apr;23(1):23-7. doi: 10.1177/0022034511399082. Adv Dent Res. 2011. PMID: 21441476 Review.
The initial disadvantages of HAART included the need for strict adherence to prevent drug resistance, the cost that initially precluded their widespread use in the developing world, and the short- and long-term side effects. One of the most disabling long-term complications was …
The initial disadvantages of HAART included the need for strict adherence to prevent drug resistance, the cost that initially precluded thei …
Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy.
Benedini S, Terruzzi I, Lazzarin A, Luzi L. Benedini S, et al. BioDrugs. 2008;22(2):101-12. doi: 10.2165/00063030-200822020-00003. BioDrugs. 2008. PMID: 18345707 Review.
In patients with HIV-1 undergoing antiretroviral treatment, lipodystrophy is associated with peripheral fat wasting and central adiposity, dyslipidemia, insulin resistance, and increased intramuscular fat accumulation. In HIV lipodystrophy, changes in fat distributi …
In patients with HIV-1 undergoing antiretroviral treatment, lipodystrophy is associated with peripheral fat wasting and central adiposity, d …
91 results